Skip to main content
NVDA-0.89%AAPL+1.07%GOOGL+1.34%MSFT+3.46%AMZN-0.95%TSM+0.60%SPCX-2.25%AVGO+2.77%TSLA-1.00%META+1.16%LLY+0.54%SKHY+13.30%BRK-B-0.49%MU-3.67%WMT-0.46%AMD+3.24%JPM+1.05%XOM+1.17%V-0.31%JNJ+0.86%ASMLa-0.83%MA+0.08%ABBV-0.01%INTC+1.91%1398.HK+2.23%CVX+0.46%0700.HK-2.58%ORCL+10.58%COST-0.95%CSCO-0.98%KO+0.60%1816.HK+7.22%PG-0.61%UNH-0.80%BAC+0.34%3988.HK+1.66%AMAT+5.07%AP2d-1.88%CAT+0.01%0857.HK+2.91%LRCX+5.39%HD-0.30%PM+0.01%DELL-1.64%0939.HK+2.12%GE+1.17%1288.HK+1.48%MS+1.81%0005.HK-0.07%HSBA.L+0.22%NZDCAD-1.57%AUDNZD+1.51%NZDUSD-1.49%NZDCHF-1.10%GBPNZD+1.02%EURNZD+0.86%NZDJPY-0.83%CADJPY+0.75%AUDJPY+0.68%EURCAD-0.68%USDJPY+0.66%EURAUD-0.63%EURUSD-0.62%GBPCAD-0.58%USDMXN+0.54%GBPAUD-0.50%GBPUSD-0.49%CADCHF+0.46%GBPTRY+0.41%AUDCHF+0.41%USDCHF+0.39%NZDMXN+0.36%GBPHKD+0.32%USDNOK+0.32%CHFNOK+0.30%USDZAR+0.30%CHFJPY+0.29%GBPMXN-0.28%NOKJPY-0.28%USDTRY+0.28%EURCHF-0.25%AUDSGD-0.24%EURCNH-0.21%USDDKK+0.18%EURSGD-0.18%EURHKD-0.17%EURSEK-0.16%GBPJPY+0.16%USDILS+0.16%NZDSGD-0.16%USDPLN+0.15%GBPZAR+0.14%GBPSGD-0.14%EURNOK+0.14%EURGBP-0.12%USDCNH-0.12%GBPCHF-0.12%EURZAR+0.11%PLNJPY-0.11%AUDDKK-0.07%AUDCAD-0.07%AUDNOK+0.06%USDCAD-0.06%USDHKD+0.06%EURJPY+0.06%USDCOP-0.04%SGDJPY+0.03%EURPLN-0.03%USDTHB+0.02%USDSEK+0.02%EURCZK-0.02%AUDUSD+0.01%CHFSGD-0.01%USDSGD+0.01%CHFSEK0.00%EURDKK0.00%GAGUSD-2.39%XAGUSD-2.38%XPTUSD-2.23%HG1-1.18%GAUUSD-1.10%XAUUSD-1.10%XNGUSD+0.78%USOIL-0.39%S1-0.39%SUGAR+0.39%C1+0.22%W1-0.17%BTCUSD-1.61%ETHUSD+22.03%USDTUSD-0.03%XRPUSD+13.23%SOLUSD+15.69%TRXUSDT+0.62%ZECUSDT-5.24%DOGEUSD+17.55%XMRUSDT-0.31%LINKUSD+21.12%BCHUSDT-3.33%XLMUSD-2.52%UNIUSD-3.16%LTCUSD+13.00%SUIUSD-3.47%HBARUSDT-1.78%TONUSD+38.24%TAOUSDT-3.79%AAVEUSD-2.71%DOTUSDT-3.16%ICPUSDT-4.00%ONDOUSDT-3.65%WLDUSDT+0.23%ARBUSDT-4.51%JUPUSDT-5.15%ATOMUSDT-2.38%INJUSDT+1.73%STXUSDT-4.98%TIAUSDT-5.99%FETUSDT-3.56%PYTHUSDT-4.70%SEIUSDT-4.03%IMXUSDT-4.63%GRTUSDT-4.24%OPUSDT-4.06%WIFUSDT-3.90%IOTAUSDT-0.34%POLUSDT-1.09%AXSUSDT-3.83%EOSUSDT-1.00%FARTCOINUSDT+0.27%DYDXUSDT-1.71%GALAUSDT-4.01%ORDIUSDT-0.55%RONINUSDT+0.38%NOTUSDT-0.41%NVDA-0.89%AAPL+1.07%GOOGL+1.34%MSFT+3.46%AMZN-0.95%TSM+0.60%SPCX-2.25%AVGO+2.77%TSLA-1.00%META+1.16%LLY+0.54%SKHY+13.30%BRK-B-0.49%MU-3.67%WMT-0.46%AMD+3.24%JPM+1.05%XOM+1.17%V-0.31%JNJ+0.86%ASMLa-0.83%MA+0.08%ABBV-0.01%INTC+1.91%1398.HK+2.23%CVX+0.46%0700.HK-2.58%ORCL+10.58%COST-0.95%CSCO-0.98%KO+0.60%1816.HK+7.22%PG-0.61%UNH-0.80%BAC+0.34%3988.HK+1.66%AMAT+5.07%AP2d-1.88%CAT+0.01%0857.HK+2.91%LRCX+5.39%HD-0.30%PM+0.01%DELL-1.64%0939.HK+2.12%GE+1.17%1288.HK+1.48%MS+1.81%0005.HK-0.07%HSBA.L+0.22%NZDCAD-1.57%AUDNZD+1.51%NZDUSD-1.49%NZDCHF-1.10%GBPNZD+1.02%EURNZD+0.86%NZDJPY-0.83%CADJPY+0.75%AUDJPY+0.68%EURCAD-0.68%USDJPY+0.66%EURAUD-0.63%EURUSD-0.62%GBPCAD-0.58%USDMXN+0.54%GBPAUD-0.50%GBPUSD-0.49%CADCHF+0.46%GBPTRY+0.41%AUDCHF+0.41%USDCHF+0.39%NZDMXN+0.36%GBPHKD+0.32%USDNOK+0.32%CHFNOK+0.30%USDZAR+0.30%CHFJPY+0.29%GBPMXN-0.28%NOKJPY-0.28%USDTRY+0.28%EURCHF-0.25%AUDSGD-0.24%EURCNH-0.21%USDDKK+0.18%EURSGD-0.18%EURHKD-0.17%EURSEK-0.16%GBPJPY+0.16%USDILS+0.16%NZDSGD-0.16%USDPLN+0.15%GBPZAR+0.14%GBPSGD-0.14%EURNOK+0.14%EURGBP-0.12%USDCNH-0.12%GBPCHF-0.12%EURZAR+0.11%PLNJPY-0.11%AUDDKK-0.07%AUDCAD-0.07%AUDNOK+0.06%USDCAD-0.06%USDHKD+0.06%EURJPY+0.06%USDCOP-0.04%SGDJPY+0.03%EURPLN-0.03%USDTHB+0.02%USDSEK+0.02%EURCZK-0.02%AUDUSD+0.01%CHFSGD-0.01%USDSGD+0.01%CHFSEK0.00%EURDKK0.00%GAGUSD-2.39%XAGUSD-2.38%XPTUSD-2.23%HG1-1.18%GAUUSD-1.10%XAUUSD-1.10%XNGUSD+0.78%USOIL-0.39%S1-0.39%SUGAR+0.39%C1+0.22%W1-0.17%BTCUSD-1.61%ETHUSD+22.03%USDTUSD-0.03%XRPUSD+13.23%SOLUSD+15.69%TRXUSDT+0.62%ZECUSDT-5.24%DOGEUSD+17.55%XMRUSDT-0.31%LINKUSD+21.12%BCHUSDT-3.33%XLMUSD-2.52%UNIUSD-3.16%LTCUSD+13.00%SUIUSD-3.47%HBARUSDT-1.78%TONUSD+38.24%TAOUSDT-3.79%AAVEUSD-2.71%DOTUSDT-3.16%ICPUSDT-4.00%ONDOUSDT-3.65%WLDUSDT+0.23%ARBUSDT-4.51%JUPUSDT-5.15%ATOMUSDT-2.38%INJUSDT+1.73%STXUSDT-4.98%TIAUSDT-5.99%FETUSDT-3.56%PYTHUSDT-4.70%SEIUSDT-4.03%IMXUSDT-4.63%GRTUSDT-4.24%OPUSDT-4.06%WIFUSDT-3.90%IOTAUSDT-0.34%POLUSDT-1.09%AXSUSDT-3.83%EOSUSDT-1.00%FARTCOINUSDT+0.27%DYDXUSDT-1.71%GALAUSDT-4.01%ORDIUSDT-0.55%RONINUSDT+0.38%NOTUSDT-0.41%
ZB

Zenas BioPharma, Inc. (ZBIO)

NASDAQ • Healthcare

$28.77
+$1.46 (+5.4%)
Market closed

Last close at October 28, 2026 at 20:00 UTC

Open$27.1
Day Range$27.03 - $29.07
Avg. Volume (3M)597.4K
Market Cap$1.8B
52 Week Range
$13.5$44.6
Next EarningsIn 20 daysNov 18, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1M100%
Gross Profitminus cost of goods$1M100%

Fundamentals & Financials

Revenue (TTM)
$1M
Net Income (TTM)
-$484.3M
EPS (TTM)
-$9.62
ROA (TTM)
-69.03%
Current Ratio
9.93

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-328.3%Q1 2026-$4.54
-6.6%Q2 2026-$1.46
-58.0%Q3 2026-$1.77
Next

Nov 18

in 20 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Zenas BioPharma, Inc. (ZBIO) is scheduled to report earnings on November 12, 2026. Wall Street expects EPS of -$1.243 on revenue of $1.0 million. Historically, the company has beaten EPS in 2 of 8 most recent quarters, so traders may focus on any variance versus these consensus benchmarks.

View full earnings history

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops immunology-based medicines for autoimmune and inflammatory diseases. FY2025 revenue was $10.0 million. Its clinical-stage pipeline centers on antibody and fusion-protein programs rather than marketed drug franchises.

Name
Zenas BioPharma, Inc.
CEO
Leon Oliver Moulder Jr.
Website
zenasbio.com
Industry
Healthcare
Year Founded
2019
Employees
167

Today's Snapshot

AI-generated

The day ended with ZBIO 5.4% higher at 28.77, while its sector was flat. Zenas BioPharma drew a renewed Buy rating from Citi bank analysts, who kept a $48 price target.

Trading Volume

Below 10d avg (499.0K)

390.5K

vs S&P 500 Today

Strong Outperformance

+5.11%

Updated: October 28, 2026 at 20:26 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
ZBIO displays a cautiously bullish setup with the stock trading above short-term moving averages and the pivot, supported by positive momentum readings and a sizable on-balance volume build. Momentum indicators are favorable while RSI and MACD remain neutral, indicating steady upside without overbought extremes, and the ADX shows a weak trend so directional conviction is limited. Volatility is elevated with a relatively high ATR, which could widen intraday ranges. Overall, volume and short-term price structure underpin the buy view. Technical takeaway: Buy bias supported by short-term strength and strong OBV despite a muted trend.
All signals
  • EMA (5 indicators)$27.38 - $28.38
    Buy
  • RSI (14)54.29
    Neutral
  • Stochastic %K (14, 3, 3)64.47
    Neutral
  • MACD Level (12, 26)-0.41
    Neutral

Peers & Related Assets

IMVTImmunovant, Inc.
$29.42+1.9%
TRAXFirst Tracks Biotherapeutics Inc
$45.72+0.8%
ANNXAnnexon, Inc.
$4.04+7.5%
UPBUpstream Bio, Inc.
$2.98+6.8%
ACRSAclaris Therapeutics, Inc.
QTTBQ32 Bio Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.